Susquehanna International Group
QNCX icon

Susquehanna International Group’s Quince Therapeutics QNCX Stock Holding History

Susquehanna International Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.3K Buy
+3,063
New +$615K ﹤0.01% 12572
2025
Q1 		– Sell
-3,917
Closed -$1.46M – 13272
2024
Q4 		$1.46M Buy
+3,917
New +$1.18M ﹤0.01% 6009
2024
Q3 		– Sell
-68
Closed -$10.2K – 12830
2024
Q2 		$10.2K Sell
68
-20
-23% -$3.61K ﹤0.01% 11776
2024
Q1 		$18.7K Buy
+88
New +$21.9K ﹤0.01% 11832
2023
Q2 		– Sell
-476
Closed -$149K – 12933
2023
Q1 		$149K Sell
476
-366
-43% -$71.6K ﹤0.01% 10920
2022
Q4 		$108K Buy
842
+507
+151% +$84.8K ﹤0.01% 10896
2022
Q3 		$89K Buy
335
+100
+43% +$38.1K ﹤0.01% 11796
2022
Q2 		$104K Sell
235
-78
-25% -$55.1K ﹤0.01% 11443
2022
Q1 		$387K Sell
313
-466
-60% -$634K ﹤0.01% 9627
2021
Q4 		$1.97M Sell
779
-1,105
-59% -$6.74M ﹤0.01% 5552
2021
Q3 		$34.5M Buy
1,884
+959
+104% +$15.3M ﹤0.01% 1454
2021
Q2 		$9.8M Buy
925
+481
+108% +$4.03M ﹤0.01% 2943
2021
Q1 		$3.2M Buy
444
+179
+68% +$1.29M ﹤0.01% 4814
2020
Q4 		$1.47M Buy
265
+242
+1,052% +$2.14M ﹤0.01% 5784
2020
Q3 		$225K Buy
+23
New +$209K ﹤0.01% 9273

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group's QNCX Position: Q1 2026 in Review

Susquehanna International Group reduced its Quince Therapeutics (QNCX) stake by 50% in Q1 2026, selling an estimated $173K and leaving 863 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12876.

Susquehanna International Group first reported a position in QNCX in Q1 2021 and has held it in 17 quarters since. The position peaked at $6.12M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Susquehanna International Group held 863 shares of Quince Therapeutics worth $17.5K as of Q1 2026.
  • Susquehanna International Group sold 862 Quince Therapeutics shares in Q1 2026, an estimated $173K.
  • Quince Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12876 holding.
  • Susquehanna International Group first reported a position in Quince Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Susquehanna International Group's Quince Therapeutics position peaked at $6.12M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.